Clinical trial · Interventional
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
The Application of Goal-directed Low Central Venous Pressure Based on Hypovolemic Phlebotomy in Laparoscopic Hepatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are: 1. The safety and feasibility of HP 2. To evaluate whether HP can reduce perioperative blood transfusion ratio Participants undergoing liver resection with HP was performed by the anesthesiologist. Blood was withdrawn approximately 30 min prior to the initiation of liver parenchymal transection from central venous. The aim was to maintain the CVP between 0 to 5 cmH2O. HP volume was 5-10 mL/kg of patient body weight, generally. Participants in control group undergoing liver resection without HP.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hypovolemic phlebotomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- hypovolemic phlebotomy (HP)
- description
- patients in this group undergoing laparoscopic hepatectomy was performed with goal-directed LCVP based on hypovolemic phlebotomy (HP)
- interventionNames
- Procedure: hypovolemic phlebotomy
- type
- NO_INTERVENTION
- label
- Control
- description
- patients in this group undergoing laparoscopic hepatectomy was performed with LCVP but no hypovolemic phlebotomy (HP)
Primary outcomes (1)
- measure
- The proportion of allogeneic red blood cell products transfusion
- timeFrame
- From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of Hepatocellular Carcinoma * Preference for laparoscopic hepatectomy and patient agreement Exclusion Criteria: * Age \<18 years * Pregnancy * Refusal of blood product transfusion * Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure) * History of significant cerebrovascular disease * Restrictive or obstructive pulmonary disease * Uncontrolled hypertension * Renal dysfunction (glomerular filtration rate \<60 mL/min), * Hemoglobin \<100 g/L * Abnormal coagulation values (international normalized ratio \>1.5 not on warfarin and/or platelet count \<100 ×109/L) * Evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L) * Presence of active infection * Preoperative autologous blood donation * Patients were not allowed to receive erythropoietin at any time during the index hospitalization.
References
Publications (0)
Data not yet available